13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001819257
Total reported value
$645.5M
$645.5M
29 檔
50.4%
In Q1 2026, Patient Square Capital LP's U.S. equity holdings reached a combined market value of $645.5M, distributed across 29 disclosed stock positions.
Patient Square Capital LP executed strategic sector rebalancing during Q1 2026, establishing 7 new positions while fully exiting 6 holdings and trimming 10 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 40.13% | +3.84% | — | |
| 2 | ARGX | Argenx Se - Adr | Stock-Healthcare | 4.76% | -1.45% | +41.22% | |
| 3 | INSM | Insmed Inc | Stock-Healthcare | 4.57% | -4.57% | EXIT | |
| 4 | ONC | Beone Medicines Ltd-adr | Stock-Other | 4.24% | -0.27% | +16.20% | |
| 5 | COGT | Cogent Biosciences Inc | Stock-Other | 4.07% | -1.52% | +87.79% | |
| 6 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 3.77% | +0.95% | -23.00% | |
| 7 | BLTE | Belite Bio Inc - Adr | Stock-Other | 3.30% | -0.68% | — | |
| 8 | LEGN | Legend Biotech Corp-adr | Stock-Other | 3.18% | -3.18% | EXIT | |
| 9 | NKTR | Nektar Therapeutics | Stock-Other | 2.68% | -2.68% | EXIT | |
| 10 | DBVT | Dbv Technologies Sa-spon Adr | Stock-Other | 2.57% | -0.26% | +93.16% | |
| 11 | PHVS | Pharvaris N.V. | Stock-Other | 2.47% | +1.13% | -9.16% | |
| 12 | ABVX | Abivax Sa-adr | Stock-Other | 2.40% | +1.86% | -6.73% | |
| 13 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 2.34% | -0.28% | +66.30% | |
| 14 | CELC | Celcuity Inc | Stock-Other | 1.92% | -1.92% | EXIT | |
| 15 | EYPT | Eyepoint Inc | Stock-Other | 1.82% | -0.22% | +1.92% | |
| 16 | MRK | Merck & Co. Inc. | Stock-Healthcare | 1.71% | -1.71% | EXIT | |
| 17 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 1.67% | -0.17% | +90.78% | |
| 18 | ALLO | Allogene Therapeutics Inc | Stock-Other | 1.49% | +0.14% | -30.50% | |
| 19 | KYMR | Kymera Therapeutics Inc | Stock-Other | 1.48% | -0.64% | -28.06% | |
| 20 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 1.40% | +0.23% | -37.41% | |
| 21 | ELVN | Enliven Therapeutics Inc | Stock-Other | 1.39% | +0.28% | -35.09% | |
| 22 | CATX | Perspective Therapeutics Inc | Stock-Other | 1.20% | -1.20% | EXIT | |
| 23 | DFTX | Definium Therapeutics Inc | Stock-Other | 1.11% | -1.11% | EXIT | |
| 24 | HROW | Harrow Inc | Stock-Other | 1.03% | -1.03% | EXIT | |
| 25 | TARA | Protara Therapeutic Inc | Stock-Other | 0.95% | -0.95% | EXIT | |
| 26 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 0.91% | -0.91% | EXIT | |
| 27 | RCUS | Arcus Biosciences Inc | Stock-Other | 0.75% | +0.95% | +14.71% | |
| 28 | ASMB | Assembly Biosciences Inc | Stock-Other | 0.67% | -0.67% | EXIT | |
| 29 | SYRE | Spyre Therapeutics Inc | Stock-Other | 0.01% | -0.01% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ROIV | Roivant Sciences Ltd. | +2.2% | — | Unchanged |
| 2 | COGT | Cogent Biosciences Inc | +1.7% | +87.79% | Add |
| 3 | DBVT | Dbv Technologies Sa-spon Adr | +1.1% | +93.16% | Add |
| 4 | XENE | Xenon Pharmaceuticals Inc | +1% | +66.30% | Add |
| 5 | HROW | Harrow Inc | +1% | +2249.72% | Add |
| 6 | CATX | Perspective Therapeutics Inc | +0.5% | +43.45% | Add |
| 7 | ELVN | Enliven Therapeutics Inc | +0.4% | -35.09% | Trim |
| 8 | ARQT | Arcutis Biotherapeutics Inc | +0.4% | +90.78% | Add |
| 9 | ARGX | Argenx Se - Adr | +0.1% | +41.22% | Add |
| 10 | DNTH | Dianthus Therapeutics Inc | +0.1% | -37.41% | Trim |
| 11 | ALLO | Allogene Therapeutics Inc | 0% | -30.50% | Trim |
| 12 | RCUS | Arcus Biosciences Inc | -0.1% | +14.71% | Add |
| 13 | ASMB | Assembly Biosciences Inc | -0.3% | +7.33% | Add |
| 14 | ONC | Beone Medicines Ltd-adr | -0.3% | +16.20% | Add |
| 15 | CELC | Celcuity Inc | -0.6% | -20.83% | Trim |
| 16 | PHVS | Pharvaris N.V. | -0.8% | -9.16% | Trim |
| 17 | KYMR | Kymera Therapeutics Inc | -0.8% | -28.06% | Trim |
| 18 | SYRE | Spyre Therapeutics Inc | -1% | -99.33% | Trim |
| 19 | EYPT | Eyepoint Inc | -1.2% | +1.92% | Add |
| 20 | MIRM | Mirum Pharmaceuticals Inc | -1.3% | -23.00% | Trim |
| 21 | ABVX | Abivax Sa-adr | -1.4% | -6.73% | Trim |
| 22 | INSM | Insmed Inc | -5.4% | -41.01% | Trim |
| 23 | BLTE | Belite Bio Inc - Adr | — | NEW | New buy |
| 24 | LEGN | Legend Biotech Corp-adr | — | NEW | New buy |
| 25 | NKTR | Nektar Therapeutics | — | NEW | New buy |
| 26 | 430 | Terns Pharmaceuticals Inc | — | EXIT | Sold out |
| 27 | MRK | Merck & Co. Inc. | — | NEW | New buy |
| 28 | LQDA | Liquidia CORP | — | EXIT | Sold out |
| 29 | DFTX | Definium Therapeutics Inc | — | NEW | New buy |
| 30 | OCUL | Ocular Therapeutix Inc | — | EXIT | Sold out |
| 31 | IRON | Disc Medicine Inc | — | EXIT | Sold out |
| 32 | AVTX | Avalo Therapeutics Inc | — | EXIT | Sold out |
| 33 | TARA | Protara Therapeutic Inc | — | NEW | New buy |
| 34 | CTMX | Cytomx Therapeutics Inc | — | NEW | New buy |
| 35 | AMLX | Amylyx Pharmaceuticals Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Patient Square Capital LP reported a total U.S. public equity portfolio value of $645.5M across 29 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ROIV, ARGX, INSM) accounted for 50.4% of total reported equity market value during Q1 2026.
Top New Position Initiated
BLTE
市值: $18.6M
Top Position Liquidated / Trimmed
430
前期市值: $12.9M
During Q1 2026, Patient Square Capital LP's top holdings by market value included ROIV (40.1%)、ARGX (4.8%)、INSM (4.6%). The largest single position, ROIV, represented 40.1% of total portfolio value.
In Q1 2026, Patient Square Capital LP made 34 total portfolio adjustments, initiating 7 new buys, adding to 11 positions, trimming 10 holdings, and fully liquidating 6 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.